| 1. |
Johnson EL. Seizures and epilepsy. Med Clin North Am, 2019, 103(2): 309-324.
|
| 2. |
Lscher W, Klein P. The Pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs, 2021, 35(9): 935-963.
|
| 3. |
Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacoki netics of levetiracetam. Front Neurol, 2013, 4: 192.
|
| 4. |
Shih JJ, Whitlock JB, Chimato N, et al. Epilepsy treatment in adults and adolescents: Expert opinion, 2016. Epilepsy & Behavior, 2017, 69: 186-222.
|
| 5. |
Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2013, 54(3): 551-563.
|
| 6. |
Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev, 2017, 12: Cd011412.
|
| 7. |
Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, doubleblind, non-inferiority trial. Lancet Neurol, 2012, 11(7): 579-588.
|
| 8. |
Maria CS, Karin SL, Elin K, et al. Evidence‐based anti‐seizure monotherapy in newly diagnosed epilepsy: a new approach. Acta Neurol Scand, 2020, 142(4): 323-332.
|
| 9. |
Liwen W, Kazuichi Y, Zhen H, et al. Adjunctive levetiracetam in the treatment of Chinese and Japanese adults with generalized tonic–clonic seizures: a double‐blind, randomized, placebo‐controlled trial. Epilepsia Open, 2018, 3(4): 474-484.
|
| 10. |
Nasim T, Ashraf Z, Parisa R, et al. Levetiracetam in genetic generalized epilepsy: aprospective unblinded active-controlled trial - ScienceDirect. Epilepsy Research, 2019, 157: 106214-106214.
|
| 11. |
Haitham, A. Levetiracetam. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 167-204.
|
| 12. |
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001, 27(4): 383-391.
|
| 13. |
Deyn P, Kabatu H, D'Hooge R. Protective effect of ucb L059 against postural stimulation-induced seizures in EL mice. Neurosciences, 1992, 18: 187-192.
|
| 14. |
Lu Q, Huang YT, Shu Y, et al. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients. Medicine, 2018, 97(30): e11662.
|
| 15. |
Wang P, Yin T, Ma HY, et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res, 2015, 117: 52-57.
|
| 16. |
Zhao GX, Zhang Z, Cai WK, et al. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis. Epilepsy Res, 2021, 173: 106615.
|
| 17. |
Bae EK, Lee J, Shin JW, et al. Factors influencing topiramate clearance in adultpatients with epilepsy: a population pharmacokinetic analysis. Seizure, 2016, 37: 8-12.
|
1/5
WeChat